

PRESS RELEASE

STALLERGENES GREER'S PERSONALISED ALLERGEN IMMUNOTHERAPY MODEL ENCOURAGED BY LEADING SCIENTISTS: "ALLERGY" JOURNAL PUBLISHES ARTICLE TODAY

London (UK), September 1, 2020 – Stallergenes Greer, a biopharmaceutical company specialising in treatments for allergies, announces the publication of an article titled "Personalized Medicine for allergy treatment: AIT, still a unique and unmatched model" in the EAACI's (European Academy of Allergy and Clinical Immunology) official journal *Allergy*.

The publication marks a clear consensus on allergen immunotherapy (AIT). It was co-authored by 49 world-renowned allergy specialists from 40 countries and coordinated by Professor Giorgio Walter Canonica, Personalised Medicine, Asthma and Allergy, Humanitas University and Research (Milano, Italy) and Professor Cristoforo Incorvaia, Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, (Milano, Italy), with an unrestricted grant from Stallergenes Greer.

The article demonstrates that there is very strong evidence to show that AIT achieves its primary therapeutic goals in patients with respiratory allergies^{1,2} by reducing the frequency and intensity of symptoms, the use of rescue medications, and improving quality of life for people with allergies.

Personalised medicine is improving the effectiveness and precision of allergy diagnosis and consequently increasing the performance and treatment outcome of AIT.

"This landmark publication, which is fully aligned with Stallergenes Greer's commitment, highlights the unique role of AIT in allergy treatment encompassing the prediction of a successful treatment, the potential prevention or progression of an allergic disease, and the possibility of providing such advances at affordable costs," states Amer Jaber, EVP Operations Europe and President of Stallergenes SAS, who heads Stallergenes Greer's R&D.

AIT: a medical model of personalised healthcare

The article outlines that personalised allergy care is valuable and may also be preventive by focusing on quality of life, predictive by allowing treatment to be adjusted to the individual's response and participative by empowering the patient.

AIT is consistent with the three major needs to be met in personalised medicine:

- the identification of the molecular mechanism of the disease,
- the availability of diagnostic tools to recognise this mechanism, and
- the availability of a treatment capable of blocking the mechanism^{3,4}.

AIT delivers customised healthcare, with medical decisions, practices, and/or products tailored to the individual patient⁵.

PRESS RELEASE

Leveraging precision medicine for personalised allergy care

This tailor-made approach to diagnosis, decision-making, product choice and treatment schedules may enhance effectiveness, minimise adverse events, improve quality of life and reduce the socio-economic impact of allergies ^{6,7,8,9}.

Stallergenes Greer's purpose "Enabling precision medicine to improve life for people with allergies" is in line with the statements set out in the article. Stallergenes Greer is committed to furthering precision medicine and personalised AIT treatments to maximise treatment outcomes for patients with allergies.

Read the full article here: <https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14575>

ABOUT STALLERGENES GREER Ltd

Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).

Additional information is available at: <https://www.stallergenesgreer.com/>

CONTACT

Communications

Catherine Kress

Tel: +33 01 55 59 26 05

Email: catherine.kress@stallergenesgreer.com

¹ Roberts G, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. *Allergy*. 2018;73(4):765-798.

² Demoly P, et al. The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment. *J Allergy Clin Immunol Pract*. 2017 May - Jun;5(3):640-648.

³ Hamburg MA, Collins FS. The path to personalized medicine. *N Engl J Med*. 2010; 22; 363(4):301-4.

⁴ Passalacqua G, Canonica GW. AIT (allergen immunotherapy): a model for the "precision medicine". *Clin Mol Allergy*. 2015; 8;13:24.

⁵ Canonica GW, et al. Allergen Immunotherapy (AIT): A prototype of precision medicine. *World Allergy Organ J*. 2015;8 (1), 31 2015.

⁶ Gueguen C, et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. *J Allergy Clin Immunol*. 2016; 137:545-558.

⁷ Caillot N, et al. Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy. *J Allergy Clin Immunol*. 2017;140; 759-770.

⁸ Gueguen C, et al. IL-10 mRNA levels in whole blood cells correlate with house dust mite allergen immunotherapy efficacy. *Allergy*. 2019; 74:2223-2226.

⁹ Luce S, et al. Th2A and Th17 cell frequencies and regulatory markers as follow-up biomarker candidates for successful multifoed oral immunotherapy. *Allergy*. 2020; 75:1513-1516.